NOV 20, 2017 3:22 PM PST

Scientists Target Prostate Cancer with an Antiparasitic Drug

WRITTEN BY: Xuan Pham

Image credit: Pixabay.com

A substance found in an antiparasitic drug could block vital communication for prostate and colon cancer cells, a new study reports.

Prostate cancer represents a huge health risk for half the world’s population, as it is the most common form of cancer in men, second only to skin cancer. The American Cancer Society estimates that over 180,000 new prostate cancer cases will be diagnosed this year.

As for colon cancer, also known as colorectal cancer or bowel cancer, this is the third most common non-skin cancer type in the world. According to a recent report, the incidence of colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030.

Both types of cancer share a common signaling pathway known as Wnt (wingless)/Beta-catenin signaling. This cascade of signals help the cancer cells grow and proliferate uncontrollably. Blocking this pathway then could be a way to slow prostate and colon cancer progression, hypothesized the research team from the University of Bergen in Norway.

With that aim in mind, the team began searching for a substance that could block Wnt signaling. They landed on a compound called nitazoxanide (NTZ) that fit the bill perfectly. And results from human colon cancer cells are promising.

"We discovered that this specific substance is blocking the signaling pathway in the cancer cells, and [making] them stop growing. It is not often that researchers discover a substance that targets specific molecules as precisely as this one,” said Karl-Henning Kalland, a professor at the University of Bergen, Norway.

"We are the first researchers," he added, "who have mapped the complex molecular mechanisms involved in this process."

It’s worth noting why researchers get more excited when a pre-existing drug shows promise for a new disease. Because so much money and time are spent for every drug that’s on the market, finding new uses for these commercially available drug effectively reduces the burden on the industry and patients could have more options sooner rather than later. With the toxicity and pharmacokinetics of a drug already known, makers can shave off as much as 15 years off the pipeline to get the drug to patients' hands.

"The advantage of testing already-approved drugs," explained Prof. Kalland, "is that we know they work in the human body and have no serious side effects, which means that a future treatment may happen quicker."

But given the limited scope of this initial study, the team is tempering their optimism with caution. "At the moment," said Prof. Kalland, "we are working on how to strengthen our ongoing immune therapy against prostate cancer by using the mechanisms we discovered of the NTZ." If all goes well, they could be the first to spearhead a clinical trial to test NTZ in patients with prostate cancer.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 18, 2019
Genetics & Genomics
NOV 18, 2019
Evaluating the Genetic Damage Caused by Cancer Treatments
Now that we know more about the impact of some cancer treatments, they can be applied optimally....
NOV 20, 2019
Genetics & Genomics
NOV 20, 2019
Mining 'Junk' DNA for New Cancer Therapeutics
There are vast portions of the genome that don't code for protein, but researchers are learning more about how important they are....
NOV 25, 2019
Cell & Molecular Biology
NOV 25, 2019
Linking Intestinal Stem Cells with Increased Cancer Risk From a High-Fat Diet
The work, which used a mouse model, links stem cell activity with cellular fat consumption in a new way....
DEC 04, 2019
Cancer
DEC 04, 2019
Photon up-conversion for new cancer treatments
Scientists from the University of California, Riverside and The University of Texas at Austin have made a breakthrough in materials science that has signif...
DEC 23, 2019
Cancer
DEC 23, 2019
Sustained weight loss over 50 reduces risk of breast cancer
Research published recently in the Journal of National Cancer Institute suggests a new form of cancer prevention: losing weight and keeping it off. This st...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
Acid-Reflux Drugs May Negatively Impact Breast Cancer Survivors
Many of us have taken some form of an acid-reflux drug—especially after a meal that causes discomfort. However, now researchers are indicating that s...
Loading Comments...